Essex Bio-Technology Limited disclosed that it repurchased 273,000 ordinary shares on 30 June 2026 through on-market transactions on the Hong Kong Stock Exchange.

• Transaction details – Repurchase volume: 273,000 shares – Price range: HKD 2.62–2.69 per share – Volume-weighted average price: HKD 2.6566 per share – Total consideration: HKD 0.73 million

• Share capital impact – Issued shares (excluding treasury shares) decreased to 566.00 million from 566.27 million, a 0.048 % reduction. – Treasury share balance rose to 1.01 million shares, bringing total issued shares (including treasury) to 567.01 million. – No repurchased shares have been cancelled to date; all are held as treasury shares.

• Mandate utilisation – Shareholders authorised a buy-back mandate on 26 May 2026 for up to 56.70 million shares. – Cumulative repurchases since the mandate: 1.01 million shares, representing 0.18 % of the company’s issued share capital on the mandate date.

• Post-repurchase restrictions – In accordance with HKEX rules, the company is subject to a moratorium on new share issues or treasury share sales until 30 July 2026.

All procedures were executed under the Hong Kong Listing Rules, with board authorisation and regulatory compliance confirmed by Director Fang Haizhou.